Difamilast serves as a selective phosphodiesterase-4 (PDE4) inhibitor utilized for the treatment of atopic dermatitis and various inflammatory skin conditions, working by suppressing the overproduction… Read more
Difamilast serves as a selective phosphodiesterase-4 (PDE4) inhibitor utilized for the treatment of atopic dermatitis and various inflammatory skin conditions, working by suppressing the overproduction of pro-inflammatory cytokines. This category contains a comprehensive range of reference standards, including impurities, metabolites, and stable isotope labelled compounds specifically designed for this therapeutic agent. Pharmaceutical laboratories rely on these high-quality materials to conduct rigorous analytical testing, impurity profiling, and method validation to ensure drug efficacy and safety. By providing access to structurally characterized degradation products and related analogs, these compounds facilitate compliance with pharmacopoeial specifications and ICH guidelines during stability studies and routine quality control. The availability of these precise reference standards is essential for developing robust analytical methods that accurately detect, identify, and quantify potential impurities throughout the drug development and manufacturing lifecycle.